Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* In general, good physical health as determined by medical history and psychiatric history, suicidality assessment \& physical examination~* Men who are potentially fertile (not surgically \[eg, vasectomy\] or congenitally sterile~* Patients with Huntington's disease (HD): diagnosis of HD and with an onset of HD after 18 years of age~  * Additional criteria apply, please contact the investigator for more information~Exclusion Criteria:~* The subject has been previously exposed to ionizing radiation or radioactive substances as a result of clinical research or medical treatment in the past 10 years.~* The subject has a counterindication to having an MRI~* History of alcohol, narcotic, or any other substance dependence in the past 2 years~* Additional Exclusion criteria to patients with Huntington's disease:~* The patient has a severe motor impairment that might cause artifacts.~* Patients with a known history of Long QT Syndrome or a first degree relative with this condition.~* Treatment with any investigational product within 6 weeks of screening or patients planning to participate in another clinical study assessing any investigational product during the study.~  * Additional criteria apply, please contact the investigator for more information

- Gender: MALE
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- pridopidine (Type: EXPERIMENTAL): Pridopidine (TV-7820) capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).